Proteome Sciences (PRM) AI Stock Analysis

• Market Cap: £5.92M
• Dividend Yield: N/A
• Average Volume (3M): 476.64K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.70
• Revenue Growth: 12.19%
• EPS Growth: 18.12%
• Country: UK
• Employees: 36
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): >-0.01
• Shares Outstanding: 295,182,040
• 10 Day Avg. Volume: 209,671
• 30 Day Avg. Volume: 476,642
• PEG Ratio: -0.08
• Price to Book (P/B): -1.54
• Price to Sales (P/S): 2.05
• P/FCF Ratio: -9.56
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: 1.50p ▼(-8.54% Downside)

Proteome Sciences' overall stock score is significantly impacted by its poor financial performance, characterized by declining revenues, negative profitability, and high debt levels. The technical analysis further indicates a bearish trend, with the stock trading below key moving averages and weak momentum indicators. The negative P/E ratio and lack of dividend yield highlight valuation concerns, contributing to the low overall score.

Positive Factors

Revenue Growth

The company's ability to achieve revenue growth indicates potential market demand and successful sales strategies, supporting long-term business sustainability.

EPS Growth

Earnings per share growth suggests improved profitability and operational efficiency, which can enhance shareholder value over time.

Industry Position

Focusing on proteomics positions the company in a niche market with high growth potential, leveraging advanced technologies for competitive advantage.

Negative Factors

Negative Profitability

Ongoing operational challenges with profitability can hinder the company's ability to reinvest in growth and maintain competitive positioning.

High Debt Levels

Excessive debt can strain financial resources, limiting strategic flexibility and increasing financial risk, which could impact long-term viability.

Negative Cash Flow

Negative cash flow indicates difficulties in generating sufficient cash to fund operations, potentially leading to liquidity issues and constraining growth.

Proteome Sciences Business Overview & Revenue Model

Company Description

Proteome Sciences (PRM) is a biotechnology company specializing in proteomics and biomarker discovery. The company focuses on providing advanced analytical services and proprietary technologies aimed at understanding protein functions and their roles in diseases. Its core products include mass spectrometry-based proteomics services that aid in drug development, diagnostics, and personalized medicine across various sectors such as pharmaceuticals, biotechnology, and academic research.

How the Company Makes Money

Proteome Sciences generates revenue primarily through its contract research services, which involve offering proteomics analysis and biomarker discovery to pharmaceutical and biotechnology companies. These services are often provided on a fee-for-service basis, where clients pay for specific projects or studies tailored to their research needs. Additionally, the company may earn income from collaborations and partnerships with academic institutions and industry players, enabling shared research initiatives and technology licensing. Furthermore, Proteome Sciences could also monetize its proprietary technologies and software tools through licensing agreements, contributing to its overall revenue stream.

Proteome Sciences Financial Statement Overview

Summary

Proteome Sciences is facing substantial financial challenges across all financial statements. Declining revenues, negative profitability, and high debt levels indicate significant business risks. The negative equity and cash flow issues further exacerbate the company's financial instability.

Income Statement

The company has experienced declining revenue with a decrease from 5.03 million to 4.89 million over the last year, indicating a negative revenue growth rate. The negative EBIT and net income margins highlight ongoing operational challenges with profitability. These factors indicate financial instability in the income statement.

Balance Sheet

The company has a negative stockholders' equity, indicating that liabilities exceed assets, which is a significant concern. The debt-to-equity ratio cannot be calculated due to negative equity, but the high total debt level suggests potential solvency issues. This balance sheet position suggests high financial risk.

Cash Flow

Operating cash flow is negative, and free cash flow has worsened, indicating cash flow difficulties. The free cash flow to net income ratio is negative, reflecting challenges in generating cash relative to net income. These factors demonstrate weak cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.53M	4.89M	5.03M	23.74B	22.59B	16.95B
Gross Profit	-32.00K	670.00K	1.65M	4.77M	2.96M	2.58M
EBITDA	-1.45M	-1.51M	-1.14M	2.13M	625.00K	714.00K
Net Income	-3.33M	-3.41M	-2.44M	1.32M	72.00K	295.00K
Balance Sheet
Total Assets	8.35M	9.21M	11.46M	12.43M	10.04M	9.09M
Cash, Cash Equivalents and Short-Term Investments	263.00K	1.13M	2.03M	3.99M	2.39M	2.21M
Total Debt	15.39M	14.52M	13.47M	11.91M	11.69M	11.04M
Total Liabilities	16.93M	15.72M	14.52M	13.28M	12.82M	12.45M
Stockholders Equity	-8.58M	-6.52M	-3.07M	-843.00K	-2.77M	-3.36M
Cash Flow
Free Cash Flow	-1.48M	-1.05M	-718.00K	2.14B	8.80B	-9.07B
Operating Cash Flow	-1.21M	-826.00K	-481.00K	3.88B	10.52B	-7.74B
Investing Cash Flow	-273.00K	-224.00K	-424.00K	-21.67B	4.27B	-18.38B
Financing Cash Flow	368.00K	151.00K	-1.06M	-209.00K	-400.00K	-146.00K

Proteome Sciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.64
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:PRM, the sentiment is Negative. The current price of 1.64 is below the 20-day moving average (MA) of 1.66, below the 50-day MA of 1.88, and below the 200-day MA of 3.02, indicating a bearish trend. The MACD of -0.09 indicates Negative momentum. The RSI at 40.83 is Neutral, neither overbought nor oversold. The STOCH value of 47.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:PRM.

Proteome Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ABDX	59 Neutral	£16.95M	―	-90.48%	―	37.39%	-126.19%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GDR	51 Neutral	£10.04M	―	―	―	125.37%	22.47%
IXI	48 Neutral	£10.43M	-4.83	-13.85%	―	7.27%	39.64%
PRM	40 Underperform	£5.92M	-1.56	―	―	12.19%	18.12%
OBD	40 Underperform	£6.26M	-0.11	-333.59%	―	45.22%	55.71%
GENI	39 Underperform	£8.18M	-1.23	-181.41%	―	12.12%	54.24%

Proteome Sciences Corporate Events

Proteome Sciences Sees Growth in Services Amid Revenue Challenges

Proteome Sciences reported a decline in total revenues for the first half of 2025, attributed to global trade upheavals and cuts in US research funding. Despite these challenges, the company’s proteomics services showed significant growth, particularly in Frankfurt and San Diego, with expectations of continued demand into 2026. The company is optimistic about future revenue growth, driven by increased orders and new product developments like DXT tags for multiplexing. However, sales of TMT reagents have been impacted by reduced R&D funding, though improvements are anticipated as the industry adapts.

The most recent analyst rating on (GB:PRM) stock is a Hold with a £3.00 price target. To see the full list of analyst forecasts on Proteome Sciences stock, see the GB:PRM Stock Forecast page.